Treat-to-target SLE strategy in 10 years: Discussion of current limitations and available options for implementation in real-world clinical practice

Elena Aleksandrovna Aseeva, Sergey K. Solovyev, E. A. Pletnev, G. Koilubaeva, B. Issayeva, Evgeny Lvovich Nasonov

Rheumatology Science and Practice, 2025

Full text Open access: Gold Metadata (CSL-JSON)

DOI 10.47360/1995-4484-2025-229-238

Data confidence 70 medium

How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

In January 2013, at the initiative of the world’s leading rheumatologists Ronald F. van Vollenhoven, Josef Smolen, Marta Mosca and Matthias Schneider, a project was launched to create the “Treat-to-Target” concept for systemic lupus erythematosus (SLE). In 2014, the group published recommendations “Treat-to-Target for SLE”. The article discusses the problems of implementing the strategy in real clinical practice and discusses the proposed ways of its implementation, proposed by international experts in 2025: 5 basic principles and 11 statements.